Radiation Oncology

Radiation oncology is a medical specialty that uses radiation therapy to treat cancer. The radiation therapy channel covers all aspects of radiation oncology technology. Radiation therapy includes linear accelerators (LINAC), proton therapy, brachytherapy, image guided radiation therapy (IGRT), focused ultrasound, stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), treatment planning systems and tomotherapy.

Elekta’s latest linear accelerator, Elekta Harmony, has won a 2022 Red Dot Award for product design. Harmony, which was granted CE mark and U.S. FDA 510(k) clearance in 2020 and 2021, is a system that perfectly balances productivity, precision and versatility, making it a solution for both mature and developing markets.
News | Linear Accelerators
Elekta Harmony Linear Accelerator Earns Red Dot Award for Product Design

April 8, 2022 — Elekta’s latest linear accelerator, Elekta Harmony, has won a 2022 Red Dot Award for product design ...

Time April 08, 2022
arrow
The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board of Directors Chair Laura A. Dawson, MD, FASTRO, in response to the Centers for Medicare and Medicaid Services' (CMS) decision to delay the start of the Radiation Oncology Alternative Payment Model (RO-APM)
News | Radiation Therapy
ASTRO Remains Committed to an RO-APM that Prioritizes Value-based Care in Light of CMS Delay

April 7, 2022 — The American Society for Radiation Oncology (ASTRO) issued the following statement from ASTRO Board of ...

Time April 07, 2022
arrow
RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion China has sold together with Mevion’s HYPERSCAN proton therapy system to Tongji Hospital in Wuhan in China
News | Treatment Planning
Tongji Hospital Selects RayStation

April 7, 2022 — RaySearch Laboratories AB announces that Mevion China has placed an order for RayStation which Mevion ...

Time April 07, 2022
arrow
On Friday, April 1 at 2 p.m., the Milton and Caroll Petrie Department of Urology at Mount Sinai will host a ribbon cutting ceremony in Wagner Houses’ Community Plaza Ground, 451 East 120th Street, to celebrate the launch of the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit.
News | Prostate Cancer
Mount Sinai Health System Launches First-Ever Mobile Prostate Cancer Screening Unit in New York City

April 6, 2022 — On Friday, April 1 at 2 p.m., the Milton and Caroll Petrie Department of Urology at Mount Sinai will ...

Time April 06, 2022
arrow
Research in the March 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined data from the Ontario Cancer Registry from September 25, 2016 through September 26, 2020, to determine the impact of the COVID-19 pandemic on the number of new cancer cases detected.
News | Coronavirus (COVID-19)
New Research in JNCCN Measures Drop in Cancer Detection Due to the COVID-19 Pandemic

April 6, 2022 — Research in the March 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network examined ...

Time April 06, 2022
arrow
The American College of Radiology (ACR) has selected 22 teams as the first cohort of the ACR Learning Network, a new initiative to improve diagnostic imaging through a learning health system approach.
News | Radiology Education
New ACR Initiative Harnesses Learning Health System Approach to Improve Diagnostic Imaging

April 5, 2022 — The American College of Radiology (ACR) has selected 22 teams as the first cohort of the ACR Learning ...

Time April 05, 2022
arrow
IBA (Ion Beam Applications S.A.), a world leader in particle accelerator technology, and the University Medical Center Groningen (UMCG) announce today a four-year research collaboration agreement towards development of a new FLASH irradiation protocol for the treatment of early-stage breast cancer.
News | Women's Health
IBA and UMC Groningen Engage in FLASH Irradiation Research Collaboration for Breast Cancer

April 5, 2022 — IBA (Ion Beam Applications S.A.), a world leader in particle accelerator technology, and the University ...

Time April 05, 2022
arrow
Elekta and GE Healthcare announced today that they have signed a global commercial collaboration agreement in the field of radiation oncology, enabling them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy.
News | Radiation Oncology
Elekta and GE Healthcare Collaborate to Expand Access to Precision Radiation Therapy Solutions

April 5, 2022 — Elekta and GE Healthcare announced today that they have signed a global commercial collaboration ...

Time April 05, 2022
arrow
Serial non-contrast axial chest CTs of three study participants with prior COVID-19 pneumonia.
Feature | Radiology Business | By Melinda Taschetta-Millane
Top 10: Most Read Radiology Technology Content in March 2022

Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of ...

Time March 31, 2022
arrow
P-Cure Ltd., the provider of the most compact 360° gantry-less adaptive proton therapy system, announced today the opening of a clinical research and training site within its headquarters in Israel.
News | Proton Therapy
P-Cure Demonstrates the Proton Therapy Equipment Can Now Be Installed In Existing Radiation Therapy Rooms

March 28, 2022 — P-Cure Ltd., the provider of the most compact 360° gantry-less adaptive proton therapy system ...

Time March 28, 2022
arrow
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports Advanced Accelerator Applications, a Novartis company, as a long-term supplier for the medical radioisotope component of the newly U.S. Food and Drug Administration (FDA) approved radiotherapeutic, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treat
News | Prostate Cancer
ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

March 28, 2022 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, supports ...

Time March 28, 2022
arrow
T2w images with overlays of lesion boundaries, DWI-derived ADC, DCE-derived ??????, and CDI? for six patient cases. (a, b) Two patients with csPCa in the PZ. (c, d) Two patients with csPCa in the TZ. (e) A patient with csPCa in the PZ and insPCa in the TZ. (f) A patient with csPCa in the AS and insPCa in the PZ.
News | Magnetic Resonance Imaging (MRI)
MRI Innovation Makes Cancerous Tissue Light Up and Easier to See

March 28, 2022 — A new form of magnetic resonance imaging (MRI) that makes cancerous tissue glow in medical images could ...

Time March 28, 2022
arrow
With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC)—the Society of Nuclear Medicine and Molecular Imaging (SNMMI) celebrates one of the greatest success stories in nuclear medicine history.
News | Prostate Cancer
SNMMI Applauds FDA Approval of New Metastatic Prostate Cancer Treatment

March 23, 2022 — With today’s U.S. Food and Drug Administration (FDA) approval of 177Lu-PSMA-617—a radiopharmaceutical ...

Time March 23, 2022
arrow
A new study from Keck Medicine of USC finds that the incidence rate of metastatic prostate cancer has significantly increased for men 45 and older and coincides with recommendations against routine prostate cancer screenings.
News | Prostate Cancer
Metastatic Prostate Cancer on the Rise Since Decrease in Cancer Screenings

March 23, 2022 — A new study from Keck Medicine of USC finds that the incidence rate of metastatic prostate cancer has ...

Time March 23, 2022
arrow
Analyzing one of the largest databases of patients with cancer and COVID-19 with machine learning models, researchers from Lawrence Livermore National Laboratory and the University of California, San Francisco found previously unreported links between a rare type of cancer—as well as two cancer treatment-related drugs—and an increased risk of hospitalization from COVID-19.
News | Coronavirus (COVID-19)
Machine Learning Model Finds COVID-19 Risks for Cancer Patients

March 22, 2022 — Analyzing one of the largest databases of patients with cancer and COVID-19 with machine learning ...

Time March 22, 2022
arrow
Feature | Radiation Therapy | By Dave Fornell
7 Trends in Radiation Therapy at ASTRO 2021

Here are 7 hot radiation therapy technology trends discussed in sessions and on the expo floor at the American Society ...

Time March 21, 2022
arrow
Addison is the next generation of remote patient monitoring (RPM) technology and offers a solution to the global caregiver crisis and the ongoing COVID-19 challenges by providing health care management outside the doctor’s four walls.
News | Remote Viewing Systems
Next Generation Remote Patient Monitoring Technology Highlighted at HIMSS22

March 18, 2022 — Electronic Caregiver, a national digital health technology and services company, will debut Addison ...

Time March 18, 2022
arrow
Above a certain size, individual brain metastases are often surgically removed with the help of microsurgical resection. In stereotactic radiosurgery (SRS), in contrast, they are usually treated with a single high-dose targeted radiation using cobalt-60-gamma radiation sources.
News | Radiation Therapy
Stereotactic Radiosurgery in Brain Metastases

March 15, 2022 — Above a certain size, individual brain metastases are often surgically removed with the help of ...

Time March 15, 2022
arrow
RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) for all stages of cancer, today announced the close of an $80 million equity financing.
News | Intensity Modulated Radiation Therapy (IMRT)
RefleXion Raises $80 Million to Broaden Cancer Treatment Options

March 14, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time March 14, 2022
arrow
Convergent will use NorthStar’s Ac-225 to radiolabel its lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody, currently being investigated as a potential ground-breaking treatment for prostate cancer.
News | Prostate Cancer
NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

March 11, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time March 11, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now